Multiparameter Pluripotency Quality Control of Human iPSCs by Flow Cytometry, Tri-Lineage Differentiation, and KaryoStat Genomic Stability Assessment

Three independent passages of the candidate line (e.g., p+5, p+10, p+15 after thaw) are assessed to capture drift. Each flow panel is run in technical triplicate with >=10,000 events per marker. Tri-lineage differentiation is performed once per qualification with parallel ectoderm/mesoderm/endoderm arms (3 wells each). KaryoStat is run at the earliest and latest QC passages. Mycoplasma PCR is run on conditioned medium at each passage. A known-good reference line and a known-abnormal line are included as assay controls.

BSL-1/BSL-2 for human iPSC handling in a Class II cabinet. PFA and saponin handled in a fume hood; aldehyde waste segregated. Ethidium bromide or alternative gel stains for mycoplasma electrophoresis handled per institutional SOP with dedicated waste. gDNA extraction reagents (guanidinium salts) are irritants. Decontaminate spent culture and conditioned medium with 10% bleach. Wear gloves, coat, eye protection; segregate sharps. Mycoplasma-positive cultures are bleach-treated and discarded immediately to prevent cross-contamination.

Positive control: certified reference iPSC line should pass all criteria (>90% pluripotency markers, normal karyotype, mycoplasma-negative). Negative control for flow: isotype-matched IgG and a differentiated/fibroblast sample (OCT4-low). Mycoplasma PCR includes the kit's positive (spiked) and negative (water) templates. KaryoStat includes a known-abnormal line to confirm aberration calling. Secondary-only IF controls for tri-lineage staining. Unstained and single-stain compensation controls for the flow cytometer.

Pluripotency markers: >=90% OCT4+/SOX2+/NANOG+ and >=85% SSEA-4+/TRA-1-60+. Tri-lineage: robust PAX6 (ectoderm), brachyury/T (mesoderm), SOX17 (endoderm) staining in respective arms. Mycoplasma: negative (no target band). KaryoStat: normal copy-number profile with no recurrent culture-adaptation gains (12p, 20q11.21, 17q, 1q). Any marker <80%, missing germ layer, mycoplasma positivity, or recurrent aberration is a fail.

• Candidate human iPSC line + reference line (e.g., a certified hPSC line)
• mTeSR Plus or Essential 8; Matrigel/vitronectin coating
• STEMdiff Trilineage Differentiation Kit (or in-house ectoderm/mesoderm/endoderm media)
• Antibodies (flow): anti-OCT4 (mouse), anti-SOX2, anti-NANOG, anti-SSEA-4 (conjugated), anti-TRA-1-60 (conjugated); matched isotype controls
• Antibodies (IF): anti-PAX6, anti-Brachyury/T, anti-SOX17
• Fixation/Perm: 4% PFA, 0.1% saponin or Triton X-100, 1% BSA
• Mycoplasma detection PCR kit (e.g., PCR-based with positive/negative templates)
• KaryoStat/SNP-array genomic DNA kit; gDNA extraction kit
• LIVE/DEAD Fixable stain; Accutase; DPBS

To qualify a human iPSC line for experimental use by quantifying surface and intracellular pluripotency markers via flow cytometry, demonstrating functional tri-lineage (ectoderm/mesoderm/endoderm) differentiation capacity, screening for mycoplasma, and confirming genomic integrity by array-based karyotyping (KaryoStat/SNP array). Lines passing all release criteria are banked and certified for differentiation experiments.

1. Expand the candidate line to ~80% confluence in feeder-free conditions; reserve conditioned medium for mycoplasma PCR.
2. Flow panel: dissociate with Accutase, stain surface markers (SSEA-4, TRA-1-60) in DPBS+1% BSA (30 min, 4 C); fix/permeabilize; stain intracellular OCT4/SOX2/NANOG (45 min, RT); acquire >=10,000 live singlets per tube.
3. Tri-lineage differentiation: seed cells into ectoderm, mesoderm, and endoderm arms per kit; culture 5-7 days; fix and immunostain PAX6, brachyury/T, SOX17 respectively.
4. Mycoplasma: run PCR on conditioned medium with kit positive/negative controls; visualize on agarose gel.
5. KaryoStat: extract gDNA, submit/run SNP array; analyze copy number for recurrent aberrations.
6. Record pass/fail against release criteria; bank passing lines with documentation.

Independent variables: passage number (p+5/p+10/p+15), candidate vs. reference line. Dependent variables: % positive for each pluripotency marker, presence/absence of germ-layer markers, mycoplasma status (+/-), copy-number aberrations. Controlled variables: culture medium, coating matrix, antibody lots and dilutions, cytometer voltages/compensation, gDNA input amount, differentiation kit lot, incubation conditions.

A bona fide pluripotent, karyotypically normal iPSC line will exhibit >90% co-expression of OCT4/SOX2/NANOG and SSEA-4/TRA-1-60 by flow cytometry, will spontaneously and directedly form derivatives of all three germ layers expressing PAX6 (ectoderm), brachyury/T (mesoderm), and SOX17 (endoderm), will be mycoplasma-negative, and will carry no recurrent culture-acquired aberrations (e.g., 12p, 20q11.21, 17q gains). Failure of any criterion disqualifies the line.

Flow .fcs files gated in FlowJo: singlets -> live -> marker-positive set on isotype controls; percent-positive and MFI exported per replicate. Tri-lineage IF scored qualitatively (present/absent) and semi-quantitatively (% positive nuclei in Fiji). Mycoplasma gel scored by presence of the diagnostic band. KaryoStat .cel files analyzed in the array software (e.g., ChAS) for segmental copy-number changes >2 Mb and recurrent hotspots. Results compiled into a certificate of analysis.

1. Low pluripotency-marker percentages: spontaneous differentiation at colony edges — manually clean differentiated regions before QC and reduce passage stress. 2. High background in flow: insufficient blocking or over-permeabilization — increase BSA to 2% and titrate antibodies. 3. Tri-lineage arm fails one germ layer: kit lot or seeding density off — re-seed at recommended density and verify Activin/inhibitor activity. 4. Ambiguous mycoplasma band: run with fresh positive/negative controls and re-test from a second flask; consider an orthogonal luminescence assay. 5. KaryoStat noise/mosaicism calls: ensure >=250 ng high-quality gDNA (A260/280 ~1.8) and re-run if call rate is low.

Pluripotency percent-positive values across passages compared by repeated-measures ANOVA (alpha = 0.05) to detect drift; n = 3 passages x 3 technical replicates. Acceptance is threshold-based (>=90% for nuclear markers), not solely inferential. Inter-passage CV reported; CV > 10% flags instability. KaryoStat and mycoplasma are categorical pass/fail. Power is sufficient (n=3 technical replicates) to estimate marker positivity within +/-5% at 95% confidence.